Type II Diabetes Clinical Trial
Official title:
A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Subjects
NCT number | NCT05176210 |
Other study ID # | PS1-01 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | December 22, 2023 |
Est. completion date | July 2025 |
This is a phase I, double-blind, placebo-controlled, randomized, single- and multiple-ascending dose study to evaluate new study intervention, PS1. PS1 is a potential blood glucose control medication, which is developed by Pharmasaga Co. Ltd. planned for treating type II diabetes mellitus (T2DM). This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), food effect and potential efficacy of PS1 in subjects.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | July 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: For all cohorts, a subject is eligible for the study if all of the following apply: 1. Both genders aged 18 to 80 years, inclusive at screening 2. Body mass index (BMI) between 18.5 and 40.0 kg/m2 3. Negative test for hepatitis B surface antigen (HBsAg), Anti-HCV antibody, and human immunodeficiency virus (HIV) at screening 4. Is willing to follow the trial life style instruction and protocol procedure 5. Able to understand and sign the informed consent form. Inclusion criteria applied for healthy subjects (Cohorts 1~6) 6. Overtly healthy subject, who is considered to be generally healthy based on medical history, vital signs, laboratory tests, 12-lead EKG, and physical examination, as judged by the investigator 7. With HbA1c value of < 6.5% and fasting plasma glucose < 110 mg/dL at Screening 8. With estimated glomerular filtration rate (eGFR) > 80 ml/min Inclusion criteria applied for T2DM patients (Cohort 7 and 8) 9. Diagnosis of T2DM 10. T2DM treated with diet and exercise alone currently, for at least 2 weeks prior to Screening 11. With HbA1c level between 6.5% to 9.0% and fasting plasma glucose level between 130 mg/dL to 250 mg/dL at Screening 12. With estimated glomerular filtration rate (eGFR) > 60 ml/min 13. For patients taking medication for other chronic disease, the medication should be on a stable dose for at least 4 weeks prior to Screening, and should not be a strong CYP enzyme inhibitor or inducer Exclusion Criteria: For all cohorts, a subject meeting any of the following exclusion criteria will be excluded from study participation. 1. History of Type I diabetes mellitus 2. Under the systemic treatment of any prescription medication or over-the-counter (OTC) medication that may interfere with the safety or PK assessment judged by the investigator within 7 days before Screening 3. Received strong CYP enzyme inhibitor or inducer within 14 days before Screening 4. Received any vaccination within 14 days before Screening 5. Has required insulin therapy within the past 12 weeks 6. Known hypersensitivity to any of the components of PS1 tablet 7. History of major clinically significant hematological, renal, respiratory, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, musculoskeletal, immune, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within 3 months of Screening that may significantly alter the biomarker panel, require receiving any systemic medications, or interfere with the interpretation of data, as judged by the investigator 8. History of pancreatitis 9. Serum amylase > 1.5 × Upper Limit of Normal (ULN) or lipase > 1.5 × ULN 10. Clinically significant ECG abnormality at Screening 11. History of cancer (malignancy) or have ever received any anti-cancer therapy 12. Regular smoker Regular smoker is defined as who smokes every day (= 1 cigarette/day in average in the past 8 weeks of Screening) 13. Consumed greater than 3 units of alcoholic beverages per day in average for the past 4 weeks before Screening One unit is equivalent to one can of beer (20% alcohol; about 45 mL) 14. Received any investigational therapy from another clinical study or underwent any major surgeries within the last 12 weeks prior to Screening. 15. Took glucose-lowering medications within the last 2 weeks prior to Screening 16. Received any systemic steroids (inhaled and intranasal steroids are permitted) or other immunosuppressive medications within 4 weeks prior to Screening 17. Have ever received cell therapy or organ transplantation 18. Other conditions not suitable for participating in this study as judged by the investigator 19. Any conditions that forbid the completion of study procedures due to the local regulatory restrictions 20. Female subject of childbearing potential who: - Is lactating; or - Has a positive pregnancy test result at Screening; or - Refuses to adopt at least one form of birth control (refer to Section 5.3) from signing informed consent to the end of the study. 21. Male subject with a female spouse/partner who is of childbearing potential refuses to adopt at least one form of birth control (refer to Section 5.3) from signing informed consent to the end of the study. Exclusion criteria applied for healthy subjects (Cohorts 1~6): 22. History of type II diabetes mellitus |
Country | Name | City | State |
---|---|---|---|
Taiwan | Mingche Liu | Taipei |
Lead Sponsor | Collaborator |
---|---|
Pharmasaga Co. Ltd. |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of dose-limiting toxicity (DLT) during the DLT observation period | DLT is defined as: (1) any adverse event (AE) = Grade 3 (CTCAE v5.0) or (2) Grade 2 AE that does not resolve to grade 1 or less within 72 hours, that occurs in the DLT observation period and is causally related (possibly, probably, or definitely related) to the test article judged by the investigator. | Day 1~ Day 8 (SAD cohort); Day 1~ Day 35 (MAD cohort) | |
Secondary | Incidence of adverse events (AEs) and serious adverse events (SAEs) | All adverse events (AEs) will be assessed for severity by the investigator based on NCI-CTCAE v5.0 | SAD, FE: up to 4 weeks; MAD: up to 8 weeks | |
Secondary | Number of participants with abnormalities in Vital signs | Number of participants with abnormal systolic/diastolic blood pressure (in mmHg), respiratory rate, pulse rate (in beat per minute, bpm), and body temperature (in ?) | SAD, FE: Baseline,1~2 weeks; MAD: Baseline,1~6 weeks | |
Secondary | Number of participants with abnormalities in Laboratory examinations | Number of participants with abnormal Hematology (hemoglobin, hematocrit, RBC, platelet, WBC, WBC differentials (neutrophils, eosinophils, basophils, lymphocytes, monocytes), MCV, MCH, MCHC), biochemistry (HbA1c, fasting plasma glucose, albumin, alkaline phosphatase, ALT, AST, BUN, creatinine, cholestero1, ?-GT, total protein, total bilirubin, direct bilirubin, triglyceride, amylase, lipase, calcium, sodium, potassium, chloride), and urinalysis (pH, protein, glucose, bilirubin, urobilinogen, ketone body, specific gravity, occult blood, RBC, WBC, creatinine, ratio of albumin/creatinine) results | SAD, FE: Baseline,1~2 weeks; MAD: Baseline,1~6 weeks | |
Secondary | Acute kidney injury (AKI) marker | Urine samples will be collected for analyzing acute kidney injury (AKI) markers | SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks | |
Secondary | Number of participants with abnormalities in 12-lead electrocardiogram (EKG) | Number of participants with abnormal Ventricular rate, PR interval, QRS interval, and QT interval | SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks | |
Secondary | Number of participants with abnormalities in Physical examination | Number of participants with abnormal Physical examination results, including general appearance, skin, eyes, ears, nose, throat, head and neck (including thyroid), heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, neurological system, and other body systems | SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks | |
Secondary | Pharmacokinetics (PK) of PS1 | AUC_Area under the serum concentration-time profile | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Pharmacokinetics (PK) of PS1 | Cmax_The peak post-dose concentration | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Pharmacokinetics (PK) of PS1 | Tmax_Time at which Cmax is observed | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Pharmacokinetics (PK) of PS1 | T1/2_Terminal phase elimination half-life | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Pharmacokinetics (PK) of PS1 | MRT_Mean Residence Time | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Pharmacokinetics (PK) of PS1 | CL/F_Apparent Clearance | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Pharmacokinetics (PK) of PS1 | Volume of distribution | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Pharmacokinetics (PK) of PS1 | Rac_Accumulation ratio | Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) | |
Secondary | Potential efficacy (For Cohort 7 and 8 only) | Changes from baseline of fasting plasma glucose (FPG) at each post-treatment visit; Changes from baseline of C-peptide at each post-treatment visit; Changes from baseline of hemoglobin A1c (HbA1c) at Visit 10 and Visit 11. | MAD: Baseline, 1~6 weeks | |
Secondary | Exploratory Endpoints (For MAD only) | Changes from baseline of serum PDIA4 | MAD: Baseline, 1~6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04569214 -
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
|
Phase 2 | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01698528 -
Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration
|
N/A | |
Completed |
NCT00985114 -
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
|
N/A | |
Active, not recruiting |
NCT05120219 -
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04893135 -
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes
|
N/A | |
Not yet recruiting |
NCT05108350 -
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02586129 -
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
|
Phase 3 | |
Completed |
NCT02914743 -
Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes
|
N/A | |
Completed |
NCT04540016 -
Mass Balance and Biotransformation of [14C]HSK7653 in Human
|
Phase 1 | |
Completed |
NCT02429258 -
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
|
Phase 4 | |
Completed |
NCT01055223 -
Fracture Risk With Thiazolidinediones
|
N/A | |
Terminated |
NCT02365233 -
Fatty Liver Study in Patients With Type II Diabetes
|
Phase 4 | |
Completed |
NCT05878587 -
Burger Allen Exercises in Knee OA With Type II Diabetes
|
N/A | |
Completed |
NCT04768673 -
A Study to Investigate the PK and Safety of CKD-393
|
Phase 1 | |
Not yet recruiting |
NCT05028140 -
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
|
Phase 3 | |
Terminated |
NCT01804777 -
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
|
Early Phase 1 | |
Completed |
NCT01619332 -
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06387433 -
Effectiveness of an mHealth Mobile App
|
N/A | |
Completed |
NCT01881074 -
Periodontal Treatment Response in Type II Diabetic Patients
|